› 3ce3

X-ray diffraction
2.4Å resolution

Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in complex with a Pyrrolopyridinepyridone based inhibitor

Released:
DOI: 10.2210/pdb3ce3/pdb
PDB entry 3ce3 coloured by chain, front view.
PDB entry 3ce3 coloured by chain, side view.
PDB entry 3ce3 coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities.
Kim KS, Zhang L, Schmidt R, Cai ZW, Wei D, Williams DK, Lombardo LJ, Trainor GL, Xie D, Zhang Y, An Y, Sack JS, Tokarski JS, Darienzo C, Kamath A, Marathe P, Zhang Y, Lippy J, Jeyaseelan R, Wautlet B, Henley B, Gullo-Brown J, Manne V, Hunt JT, Fargnoli J, Borzilleri RM
J Med Chem 51 5330-41 (2008)
PMID: 18690676

Function and Biology Details

Reaction catalysed: 
ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate
Biochemical function:
Biological process:
Cellular component:
  • not assigned
Sequence domains:
Structure domain:

Structure analysis Details

Assembly composition:
monomeric (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-140186 (preferred)
Entry contents:
1 distinct polypeptide molecule
Macromolecule:
Hepatocyte growth factor receptor Chain: A
Molecule details ›
Chain: A
Length: 314 amino acids
Theoretical weight: 35.44 KDa
Source organism: Homo sapiens
Expression system: Spodoptera frugiperda
UniProt:
  • Canonical: P08581 (Residues: 1049-1360; Coverage: 23%)
Gene name: MET
Sequence domains: Protein tyrosine and serine/threonine kinase
Structure domains:

Ligands and Environments

1 bound ligand:
Ligand 1FN 1 x 1FN
No modified residues

Experiments and Validation Details

Entry percentile scores
X-ray source: APS BEAMLINE 17-ID
Spacegroup: P212121
Unit cell:
a: 43.04Å b: 49.137Å c: 159.324Å
α: 90° β: 90° γ: 90°
R-values:
R R work R free
0.21 0.206 0.275
Expression system: Spodoptera frugiperda

Quick links

Citations

4 review citations

AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.
Zhu et al. (2019)
3 more

9 mentions without citation

The azaindole framework in the design of kinase inhibitors.
Mérour et al. (2014)
8 more